In order to promote the all-round development of primary oncology medicine and further improve the diagnosis and treatment of primary tumor diseases, Chengdu High-tech Medical Association held the "2022 Life Journey Anti-Cancer Series Academic Activities-Western Tour (esophageal cancer 1)" in Chengdu on January 16, 2022. ", this forum invited well-known experts in related fields to give lectures on esophageal tumor immunotherapy and other related content, and to share the latest research progress.

The meeting was opened and summarized by Prof. Han Yongtao from Sichuan Cancer Hospital and Prof. Wang Zhen from Cancer Hospital of Chinese Academy of Medical Sciences. Professor Dai Liang from Peking University Cancer Hospital focused on the interpretation of "2021 Progress in Perioperative Treatment of Esophageal Cancer"; Professor Guo Xufeng from Shanghai Chest Hospital focused on sharing "Surgical Treatment of Esophageal Cancer"; Professor Leng Xuefeng from Sichuan Cancer Hospital shared He shared his experience in the management of esophageal cancer in the whole process; according to the teaching content of the participating experts, all the professors launched a stimulating discussion.

This conference provides a platform for clinical doctors and scientific researchers to exchange diagnosis and treatment technology and academic research results, which is conducive to academic discussions and exchanges of classic cases and cutting-edge technologies in the promotion of tumor immunity, and establishes comprehensive and standardized treatment of oncology medicine. concept. It is of great significance to promote high-quality clinical research in the field of medical oncology and promote the level of clinical scientific research.